Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.67 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 2/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
| ▸ | JUN | P05412 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylcurcumin SCHEMBL3487103 | 0.92 | HDAC1 (0.78) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| Dimethylcurcumin SCHEMBL29354872 | 0.92 | HDAC1 (0.78) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| Dimethylcurcumin SCHEMBL3487105 | 0.92 | HDAC1 (0.78) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| Dimethylcurcumin SCHEMBL3686107 | 0.92 | HDAC1 (0.78) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| SCHEMBL18758184 | 0.88 | HDAC1 (0.66) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| SCHEMBL9907008 | 0.86 | HDAC1 (0.63) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| Dimethylcurcumin SCHEMBL2528940 | 0.85 | HDAC1 (0.69) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| SCHEMBL16888009 | 0.85 | GSK3B (0.81) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| Dimethylcurcumin SCHEMBL2528943 | 0.85 | HDAC1 (0.69) | HDAC1HDAC2HDAC8GSK3BNFE2L2 | |
| SCHEMBL14112832 | 0.85 | HDAC1 (0.69) | HDAC1HDAC2HDAC8GSK3BNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198323-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198323-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | The University of North Carlina at Chapel Hill (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | The University of North Carlina at Chapel Hill (US) | 2010-08-05 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | HDAC1 105/4885HDAC2 328/4885HDAC8 82/4885 |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | HDAC1 105/4885HDAC2 328/4885HDAC8 82/4885 |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | HDAC1 105/4885HDAC2 328/4885HDAC8 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.